As the United States barrels toward the 2026 midterm elections, a seismic shift in the nation’s social...
Written by Douglas Feil, NBCF Chief Program Officer Medical Disclaimer: The information provided in this article is...
For decades, the standard path for women undergoing breast reconstruction following a mastectomy has been a binary...
In a sobering turn of events for the biotechnology sector, Caribou Biosciences—a company born from the pioneering...
In the high-stakes world of pharmaceutical development, the path from a lead compound to a human clinical...
In the rapidly shifting landscape of modern medicine, the intersection of patient advocacy, clinical expertise, and genomic...
In the complex landscape of international diplomacy and global public health, few relationships have been as foundational—or...
As the landscape of breast cancer care continues to evolve, the focus for patients is shifting from...
Oklahoma City, OK – In a significant leap forward for cancer research, scientists at the University of...
Disappointing Phase III results for ArriVent BioPharma’s lead candidate, firmonertinib, in the treatment of non-small cell lung...
